Matrix Labs has posted a consolidated net profit of Rs 338 million on consolidated net sales of Rs 4422 million for the quarter ended 30th June 2006 as compared to the net income of Rs 253 million on sales of Rs 1543 million in the corresponding quarter of the previous year.

Earnings per share (EPS) on the consolidated basis as on 30th June 2006 works out to Rs 8.80 annualized (basic) on a paid up equity capital of Rs 307 million with a face value of Rs 2 per share.

There has been increase in Research & Development expenses to a level of Rs 177 million as against Rs 147 million in the immediate preceding quarter, an increase of Rs 30 million (20 per cent).

Generic APIs accounted for 29 per cent of the total revenues, ARVs accounted for 23 per cent, finished dosage forms accounted for 26 per cent, hospital products for 14 per cent and CRAM segment contributed about eight per cent of revenues.